Building on the strong momentum it has been displaying since the beginning of this year, CVS Health Corporation (NYSE: CVS) on Wednesday posted third-quarter financial results that were ahead of Wall Street targets.
The company said its total revenue shot up 36.5% to $64.8 billion, exceeding average analysts’ consensus of $63 billion.
The strong growth in topline helped the healthcare company generate adjusted EPS of $1.84 per share in Q3, which was 7 cents ahead of the street consensus.
“All of our core businesses performed in line with or above expectations, reflecting strong operational execution. As a result, we delivered strong growth and generated robust operating cash flow, which enabled us to continue to deliver while returning capital to our shareholders,” CEO Larry Merlo stated.
READ: Alteryx CFO Kevin Rubin on Q4 outlook, stock sell-off and the possibility of getting acquired
Outlook raised
Thanks to the strong results, the company raised and narrowed its Adjusted EPS guidance range to $6.97 – $7.05 from the prior projection of $6.89 – $7.00.
Meanwhile, outlook on GAAP operating income was slashed to $11.77 billion – $11.95 billion from the earlier range of $11.82 billion – $12.02 billion.
CVS shares gained 1.5% during pre-market hours.
Most Popular
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss
Key metrics from Nike’s (NKE) Q2 2025 earnings results
NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net
FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips
Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,
Comments
Comments are closed.